Search Details

Word: blowouts (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

Fitzpatrick shook off the interception and his first ever lost fumble to post six touchdowns—four passing and two rushing—in the eventual blowout. He finished the day with 410 total yards, going 20 of 35 for 361 yards in the air—the fourth best single game passing yardage in school history—and rushing for 49 more...

Author: By Brenda Lee, CRIMSON STAFF WRITER | Title: Crimson Makes Opening Statement | 9/29/2003 | See Source »

After a close call against No. 16 Richmond on Saturday, the Crimson suffered its second loss of the season at the hands of No. 3 Maryland. However, though the 5-1 score may have indicated the game was a blowout, Harvard left the field knowing it had played its best game...

Author: By Wes Kauble, CONTRIBUTING WRITER | Title: Field Hockey Faces Huskies | 9/24/2003 | See Source »

After a close call against No. 16 Richmond on Saturday, the Crimson suffered its second loss of the season at the hands of No. 3 Maryland. However, though the 5-1 score may have indicated the game was a blowout, Harvard left the field knowing it had played its best game...

Author: By Wes Kauble, CONTRIBUTING WRITER | Title: NO HEADLINE | 9/23/2003 | See Source »

...discipline to science and medicine." In other words, he wants to inject a sobering dose of planning and budgets into an industry that has more hype than earnings in its bloodstream. Mullen's vision didn't immediately play well with biotech investors, many of whom prefer the promise of blowout growth to steady profits. Shares of both companies dropped sharply. Biotech's allure since the benchmark Genentech ipo 23 years ago has been its promise to deliver wonder drugs that will cure feared ailments like cancer and Alzheimer's; compared to that, budgetary discipline seems pretty dull. Yet with...

Author: /time Magazine | Title: Will This Experiment Work? | 7/13/2003 | See Source »

Mullen's vision didn't immediately play well with biotech investors, many of whom prefer the promise of blowout growth to steady profits. Shares of both companies dropped sharply. Who needs another giant drug company pumping out me-too pills, focusing on stuff it already makes and pinching pennies to deliver a steady income? Biotech's allure since the benchmark Genentech IPO 23 years ago has been its promise to deliver wonder drugs that will cure feared ailments like cancer and Alzheimer's. Yet with an exhaustingly long list of failed products and failed companies in its brief past...

Author: /time Magazine | Title: Will This Experiment Work? | 7/7/2003 | See Source »

Previous | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | Next